Cumulex N.V. Overview
Cumulex NV is a 70-year-old Belgian listed company that has no operating activities. It describes itself as a stock-exchange vehicle without activities. Its value proposition is the listing itself: a regulated-market quotation on Euronext Brussels that a private company could use to go public through a reverse listing, or into which a controlling shareholder could contribute businesses.
The company descends from Sucraf, which co-owned a sugar plantation and refinery in the Democratic Republic of Congo (Sucrerie de Kiliba). That stake is now carried at EUR 1. Since about 2014 the shell has been controlled and financed by the Dutch investment company Value8, which holds 75.75% of the votes and an interest-free claim of EUR 2.52 million on Cumulex.
The only acquisition attempt since the rename was a planned purchase of Value8's 65% stake in Dutch demolition firm AA Circular. Shareholders approved it in January 2023, but it was never completed. The equity story is therefore entirely about deal optionality, set against negative equity of EUR −2.54 million.
Company's own description (latest annual report, FY2025, paraphrased from Dutch). Cumulex, formerly Sucraf, is a Belgian NV. The board's strategy is to bring new activities into the company. It will look for suitable opportunities in consultation with counterparties. A reverse listing, in which a private company obtains a stock-exchange listing through Cumulex, is explicitly one of the routes. Candidates are screened on three criteria:
-
an attractive value proposition for security holders;
-
profitability and earnings per share;
-
long-term value-growth prospects.
The primary objective remains medium- to long-term value creation. The board reserves the right to depart from these criteria if better opportunities arise. It also notes that, although not currently expected, restarting operations or liquidating the company could prove more attractive than a reverse listing (AR FY2025, board report).
The homepage frames the company similarly. It calls Cumulex a listed company without activities, invites investment proposals, and lists six screening attributes (Cumulex website, accessed Oct 2026):
-
value proposition;
-
profitability;
-
EPS contribution;
-
long-term value growth;
-
good track record;
-
strong management.
Independent characterisation.
Business model: a listed shell ("beurshuls"). It generates no revenue and incurs about EUR 70–90k a year in listing-maintenance costs: the statutory auditor, FSMA, Euronext, Euroclear and mandatory legal notices (AR FY2025). Value8 funds these costs through non-interest-bearing advances.
Revenue model mix: product 0%, service 0%, subscription 0%, licensing 0%. Revenue has been nil every year FY2021–FY2025 (statutory income statements).
Value chain position: none in an industrial sense. In capital-markets terms, Cumulex sits at the "listing supply" end of the market. It offers listing status, a shareholder register, and about EUR 6.44 million of Belgian tax-loss carryforwards to a would-be acquirer. Use of those losses is uncertain after a change of control (AR FY2025, note 6.13).
Customer types: none in the conventional sense. The target "customers" are (a) private companies seeking a quotation, and (b) Value8 portfolio companies that could be injected.
End-markets served: none at present. Data vendors classify the company variously as "Non-operating Establishments" (StockAnalysis), "Activities of holding companies and financing conduits" (FinancialFilings), and "consumer goods", a legacy sugar classification (Beursgenoten/ShareCompany). These classifications conflict, which reflects the absence of any operating business.
Legacy asset. Cumulex still records a 33% interest (32,997 capital shares) in Sucrerie de Kiliba-Sucki Sarl, DRC. Historical cost is EUR 9,317,680.58, fully impaired to EUR 1. A related receivable of nominal EUR 1,340,664.52 is also written down to EUR 1. The board states there are no developments regarding Kiliba and no expectation of any proceeds (AR FY2025).
Strategy
Stated strategy themes (latest filings, paraphrased).
-
Bring in or acquire operating businesses to create long-term value (H1 2025 release; AR FY2025).
-
Pursue investments, stakes in companies and/or a reverse listing, so that sustainable value growth becomes possible and a base exists that is proportionate to listing costs (H1 2026 release, 31 Jul 2026).
-
Screen targets on an attractive value proposition, a positive effect on profitability and EPS, and healthy long-term growth (FY2024 and FY2025 releases).
-
Keep alternative outcomes open: restarting operations or liquidation, if more value-accretive (AR FY2025).
-
Possibly strengthen the balance sheet by converting Value8's claim into (preferred) securities on market-conform terms, potentially including the EUR 1.2m conditionally waived debt. The board states these proposals are not yet concrete (AR FY2025).
Initiatives in the last 24 months
Medium-term financial targets / guidance: none published.
Investor day: none held.
Products & Services
Cumulex has no products, brands, platforms or service offerings. Its de facto "offerings" are listed below for completeness. None are priced or sold.
Legacy (historical) business. Sucraf's historical business was the co-ownership of a sugar plantation and refinery at Kiliba (DRC). No specifications, volumes or product data are publicly disclosed in the documents reviewed.
Product Portfolio
| "Offering" | Description | Target counterparty | Since | Pricing model | Source |
|---|---|---|---|---|---|
Reverse-listing vehicle | A Euronext Brussels regulated-market quotation available to a private company that merges into, or is contributed to, Cumulex | Private companies seeking a listing; Value8 portfolio companies | Strategy stated since at least 2021 | Not publicly disclosed (would be negotiated per deal) | cumulex.be; AR FY2025 |
Investment platform | Vehicle for "investments, taking stakes in companies and/or a reverse listing" | Same as above | Restated 31 Jul 2026 | — | Press release 31 Jul 2026 |
Tax-loss carryforwards (embedded attribute) | EUR 6,444,660 of Belgian carry-forward losses, usable without time limit in principle. Survival after a change of control is uncertain unless the change meets "legitimate financial or economic needs" under the Belgian Income Tax Code (WIB 1992) | Acquirer of control | Accumulated mostly pre-2011 | — | AR FY2025 note 6.13 |
“—” = not publicly disclosed.
Financial Narrative
Basis of preparation. The accounts are Belgian GAAP statutory accounts under the Royal Decree of 29 April 2019, not IFRS. They are unconsolidated. All figures are in EUR (not thousands), taken from audited balance sheets and income statements:
-
FY2021 and FY2022: AR FY2022.
-
FY2023: AR FY2023.
-
FY2024 and FY2025: AR FY2025.
Income statement
Notes:
-
FY2021 YoY is shown as 0 because the FY2020 comparable is EUR −29k per the FY2020 press release, a +124% jump not shown in the table.
-
Gross, operating, EBITDA and net margins are undefined (division by zero revenue). The revenue CAGR is undefined.
-
The operating cost CAGR for FY2021–FY2025 is +3.6% a year (analyst calc.).
-
Cumulative net losses for FY2021–FY2025 total EUR 377,338.
Press-release error: the FY2023 press release compares the FY2023 loss of EUR −76k with "2021: −91 thousand". The −91k figure is in fact FY2022. This is a labelling error in the company's own release.
Commentary. The cost base consists entirely of listing-compliance costs. The FY2022 spike (+40.8%) is explicitly attributed in AR FY2022 to the preparation of the AA Circular acquisition: three shareholder meetings, a special board report and advisory work. FY2023 also carried some deal-preparation cost per AR FY2023. Costs then normalised at about EUR 70–75k.
The statutory auditor's fee alone is a large share of the cost base:
Sources: AR notes 6.16; ratios are analyst calculations. Directors and major shareholders received no remuneration in FY2022–FY2025 (AR FY2025).
Half-year results history
Sources: half-year press releases (4 Sep 2020, 13 Sep 2021, 5 Aug 2022, 29 Sep 2023, 26 Sep 2024, 30 Sep 2025, 31 Jul 2026). H1 2026 EPS was −7.7 euro cents (H1 2025: −7.5 cents). H1 2023 is cited as −45k by the company; ABM FN reported the same. The H1 2022 release gives −34k, while the H1 2023 release cites the H1 2022 comparable as −35k (rounding discrepancy).
Balance sheet
The FY2021 increase in the Value8 claim is shown as 0 because it is not disclosed in the reviewed documents.
Key off-balance-sheet items (AR FY2025 notes 6.14 and 6.15):
-
Conditional debt waiver of EUR 1,205,262. Value8, as assignee of the Sopex claim, has waived this amount subject to a "retour à meilleur fortune" clause, so it would revive if Cumulex's finances recover.
-
Letter of support. Value8 has given an irrevocable and unconditional letter of support guaranteeing continuity until at least the AGM of 14 June 2027.
-
Authorised capital. The articles authorise a capital increase of up to EUR 1,835,000.
-
No interest. The Value8 claim bears no interest.
Commentary. The balance sheet is a pure liability structure. Assets are effectively nil (EUR 104 at FY2025). Equity has deteriorated every year by roughly the annual loss, because Value8 funds the cash burn with interest-free advances that add one-for-one to liabilities. The equity deficit (−EUR 2.54m) is larger than issued capital (EUR 1.84m).
Cash flow (no cash-flow statement published; analyst derivation)
Cumulex files abbreviated Belgian statutory accounts and does not present a cash-flow statement. The table below derives operating cash flow as: change in cash minus the increase in the related-party claim. This is an approximation; FY2021 is not derivable from the reviewed documents.
AR FY2025 confirms that no own shares were acquired in the year.
Commentary. Cumulex has no self-generated cash flow. It typically ends each year with near-zero cash (EUR 102–3,203). Value8 drip-feeds about EUR 72–90k a year, which is effectively equity support booked as debt.
Ratios
Computable ratios (analyst calculations from statutory accounts)
Ratios that are not meaningful
Trend summary and inflections.
2021–2022 inflection: The AA Circular project lifted costs to a peak of EUR 91k.
2023–2024: Costs normalised once the deal stalled.
2025: Costs rose 6%, consistent with a higher audit fee (EUR 32.8k).
H1 2026: Steady at −EUR 42k.
The structural driver is unchanged: a fixed listing cost with no revenue. Each year adds about EUR 75k to Value8's claim and the equity deficit.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Stake | Carrying value (FY2025) | Status |
|---|---|---|---|---|
Value8 NV (Bussum, NL) | Parent / controlling shareholder | 75.75% of votes in Cumulex | — | Active; funds Cumulex |
Cumulex NV (Diegem, BE) | Listed company | — | — | Dormant shell |
Sucrerie de Kiliba-Sucki Sarl (DRC) | Associate (legacy) | 33% (32,997 shares) | EUR 1 (stake) + EUR 1 (receivable) | No developments; no proceeds expected |
Revenue by Segment (EUR) and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Segment revenue (EUR) | 0 | 0 | 0 |
Segment operating result (EUR) | -75,906 | -70,558 | -74,797 |
Segment pre-tax result (EUR) | -75,906 | -70,558 | -74,797 |
% contribution to total revenue | 0 | 0 | 0 |
Operating cost YoY growth (%) | -16.8 | -7.0 | 6.0 |
Income Statement (EUR) and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR) | 0 | 0 | 0 | 0 | 0 |
Gross profit (EUR) | 0 | 0 | 0 | 0 | 0 |
Operating costs — services and miscellaneous goods (EUR) | 64,825 | 91,252 | 75,906 | 70,558 | 74,797 |
Operating income / EBIT (EUR) | -64,825 | -91,252 | -75,906 | -70,558 | -74,797 |
EBITDA (EUR, no D&A booked) | -64,825 | -91,252 | -75,906 | -70,558 | -74,797 |
Financial result (EUR) | 0 | 0 | 0 | 0 | 0 |
Pre-tax income (EUR) | -64,825 | -91,252 | -75,906 | -70,558 | -74,797 |
Income tax (EUR) | 0 | 0 | 0 | 0 | 0 |
Net income (EUR) | -64,825 | -91,252 | -75,906 | -70,558 | -74,797 |
EPS per voting instrument, 550,000 basis, as reported by company (EUR) | -0.12 | -0.17 | -0.14 | -0.13 | -0.14 |
EPS per listed share, 440,000 basis, analyst calc. (EUR) | -0.15 | -0.21 | -0.17 | -0.16 | -0.17 |
Diluted EPS (EUR, no dilutive instruments outstanding) | -0.12 | -0.17 | -0.14 | -0.13 | -0.14 |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Operating cost YoY change (%) | 0 | 40.8 | -16.8 | -7.0 | 6.0 |
Auditor Fee by Fiscal Year
| Fiscal year | Auditor fee (EUR) | Share of total costs |
|---|---|---|
FY2022 | 27,500 audit + 7,508 other assurance | 38% |
FY2023 | 28,135 audit + 2,905 other | 41% |
FY2025 | 32,840 audit | 44% |
Key Financials
| Metric | H1 2020 | H1 2021 | H1 2022 | H1 2023 | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|---|---|---|---|
Net / operating result (EUR K) | -14 | -38 | -34 | -45 | -32 | -41 | -42 |
Balance Sheet (EUR)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR) | 8,606 | 148 | 211 | 3,205 | 104 |
Financial fixed assets — Kiliba stake + receivable (EUR) | 2 | 2 | 2 | 2 | 2 |
Cash and equivalents (EUR) | 8,604 | 146 | 209 | 3,203 | 102 |
Trade payables (EUR) | 16,240 | 35,533 | 29,026 | 30,078 | 24,274 |
Other short-term liabilities (EUR) | 2,220,229 | 2,283,730 | 2,366,206 | 2,438,706 | 2,516,206 |
of which owed to Value8, non-interest-bearing (EUR) | 2,188,706 | 2,278,706 | 2,366,206 | 2,438,706 | 2,516,206 |
Short-term debt — total liabilities due within 1 year (EUR) | 2,236,469 | 2,319,263 | 2,395,232 | 2,468,784 | 2,540,480 |
Long-term debt (EUR) | 0 | 0 | 0 | 0 | 0 |
Net debt — Value8 claim minus cash, analyst calc. (EUR) | 2,180,102 | 2,278,560 | 2,365,997 | 2,435,503 | 2,516,104 |
Issued capital (EUR) | 1,835,000 | 1,835,000 | 1,835,000 | 1,835,000 | 1,835,000 |
Legal reserve (EUR) | 6,030 | 6,030 | 6,030 | 6,030 | 6,030 |
Accumulated losses carried forward (EUR) | -4,068,893 | -4,160,145 | -4,236,051 | -4,306,609 | -4,381,406 |
Total equity (EUR) | -2,227,863 | -2,319,115 | -2,395,021 | -2,465,579 | -2,540,376 |
Goodwill and intangibles (EUR) | 0 | 0 | 0 | 0 | 0 |
Working capital — current assets minus current liabilities (EUR) | -2,227,865 | -2,319,117 | -2,395,023 | -2,465,581 | -2,540,378 |
Annual increase in Value8 claim (EUR) | 0 | 90,000 | 87,500 | 72,500 | 77,500 |
Cash Flow (EUR)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Change in cash (EUR) | -8,458 | 63 | 2,994 | -3,101 |
Funding from Value8 — increase in claim (EUR) | 90,000 | 87,500 | 72,500 | 77,500 |
Implied operating cash flow (EUR) | -98,458 | -87,437 | -69,506 | -80,601 |
Capex (EUR) | 0 | 0 | 0 | 0 |
Free cash flow — implied (EUR) | -98,458 | -87,437 | -69,506 | -80,601 |
Dividends paid (EUR) | 0 | 0 | 0 | 0 |
Share buybacks (EUR) | 0 | 0 | 0 | 0 |
Financial Ratios (x) and Balance Sheet (EUR)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Current ratio (x) | 0.0038 | 0.0001 | 0.0001 | 0.0013 | 0.0000 |
Total liabilities / equity (x) | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 |
Value8 claim per voting instrument, 550,000 basis (EUR) | 3.98 | 4.14 | 4.30 | 4.43 | 4.57 |
Book equity per voting instrument, 550,000 basis (EUR) | -4.05 | -4.22 | -4.35 | -4.48 | -4.62 |
Asset turnover (x) | 0 | 0 | 0 | 0 | 0 |
Financial Analysis
| Ratio | Status | Reason |
|---|---|---|
ROE | Not meaningful | Negative net income divided by negative equity yields a spurious positive figure |
ROA | Not meaningful | Total assets of EUR 104–8,606 produce four- to five-figure negative percentages |
ROIC | Not meaningful | Invested capital is negative |
Net debt / EBITDA | Not meaningful | EBITDA is negative (FY2025: net debt EUR 2.52m vs EBITDA −EUR 0.075m) |
Interest coverage | Undefined | No interest expense; the Value8 claim is interest-free |
Debt / equity | Not meaningful | Equity is negative |
Cash conversion cycle | Not applicable | No revenue, inventory or receivables |
Gross / operating / EBITDA / net margins | Undefined | Zero revenue |
Geographic Revenue
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue — Belgium (EUR) | 0 | 0 | 0 | 0 | 0 |
Revenue — Rest of Europe (EUR) | 0 | 0 | 0 | 0 | 0 |
Revenue — Africa / DRC (EUR) | 0 | 0 | 0 | 0 | 0 |
Revenue — Total (EUR) | 0 | 0 | 0 | 0 | 0 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price | EUR 0.66 (last trade 30 Sep 2026) | Beursgenoten |
52-week range | EUR 0.66 – 0.755 | StockAnalysis (as of Jul 2026) |
Market cap change (as shown) | −9.0% (period basis not specified by vendor) | StockAnalysis |
1-year performance | Not reliably determinable. The price sits at the 52-week low of EUR 0.66, against a high of EUR 0.755 | StockAnalysis |
3-year performance | Not publicly verifiable from reviewed sources | — |
5-year performance | Not publicly verifiable. An IEX.nl reader comment on 20 Dec 2021 cited a price of about EUR 2.94 on that day's active trading | IEX.nl comment |
Beta | 0.75 (vendor figure; statistically unreliable given illiquidity) | StockAnalysis |
Liquidity | Prior-session volume of 4 shares; frequent no-trade days | Beursgenoten |
Valuation Snapshot — Market cap
| Metric | Value |
|---|---|
Market cap (440,000 shares × 0.66) | 290,400 |
Plus: Value8 claim | 2,516,206 |
Less: cash | 102 |
Enterprise value | 2,806,504 |
P/E | Not meaningful (negative EPS) |
EV/EBITDA | Not meaningful (negative EBITDA) |
EV/Sales | Not meaningful (zero sales) |
P/B | Not meaningful (negative book value) |
Market cap / annual cash burn | ≈3.9x (290,400 / 74,797) |
Capital Markets
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Buybacks (EUR) | 0 | 0 | 0 | 0 | 0 |
Capital Markets — Moody's / S&P / Fitch
| Item | Detail |
|---|---|
Moody's / S&P / Fitch | Not rated |
Debt instruments | No bonds or bank debt. Total financial debt is the EUR 2,516,206 Value8 current-account claim (interest-free, short-term) |
Debt maturity profile | 100% classified as due within one year, but supported by the letter of support to Jun 2027 |
Convertible bond (AA Circular) | Approved but never issued; no outstanding conversion rights (AR FY2025 note 6.7.1 shows nil convertibles) |
Analyst Conclusions
Management guidance: none quantitative. Qualitatively, management continues to pursue investments, stakes and/or a reverse listing (H1 2026 release).
Consensus: no analyst coverage, so there is no consensus.
Run-rate expectation (analyst). Absent a transaction, FY2026 should show a loss of about EUR 75–85k (H1 2026: EUR 42k). Equity would deteriorate to about −EUR 2.62m, and the Value8 claim would rise to about EUR 2.6m.
Bull case (data-grounded)
-
Cheap option on a deal. For EUR 290k of market cap, investors hold an option on a reverse listing. The one deal structured so far implied a pro forma diluted EPS of about EUR 0.20 (press release 1 Feb 2022), roughly 30% of today's share price.
-
A motivated sponsor. Value8 has funded the shell for over a decade, renewed its support to 2027, and has a documented record of moving assets between its listed vehicles.
-
Balance-sheet repair would unlock value. Converting the EUR 2.52m claim, plus potentially the EUR 1.21m conditional waiver, would restore positive equity. Combined with EUR 6.44m of tax losses, this could make the shell attractive to a profitable target.
Bear case (data-grounded)
-
Structural cash drain. EUR 377k of cumulative losses over FY2021–FY2025 are added one-for-one to a senior related-party claim that ranks ahead of shareholders.
-
Minority value is likely to be diluted heavily. Any recapitalisation or injection is priced against negative equity. The AA Circular terms would have reduced minorities from about 24% to about 9%.
-
Execution and governance record. One deal in five years, unfinished three years after approval. Auditor-flagged statutory breaches. Illiquid trading that prevents an orderly exit.
Catalysts and monitorables (next 12 months)
Concluding analyst verdict. Cumulex NV is best understood as a listed legal shell held in reserve by Value8, not as an operating company. Its financial statements are almost purely a ledger of compliance costs. Annual costs of about EUR 75k are funded by interest-free advances from its controlling shareholder. Equity stands at −EUR 2.54 million, total assets are EUR 104, and there are no employees, no revenue and no analyst coverage.
The only substantive attempt to change this was the 2022–2023 plan to acquire Value8's 65% stake in Dutch demolition contractor AA Circular. Shareholders approved it, but the target's bank never consented. The plan has been effectively dormant since early 2024.
The June 2026 board expansion is a genuine, if overdue, response to auditor-flagged breaches of Belgian company law. It does not change the economics. With Frank Lagerveld's death weeks after his appointment, the board is again below its intended size.
For a minority investor, the position is a deep-out-of-the-money option. Upside depends on three things happening together: Value8 sourcing an attractive asset, converting its EUR 2.5 million claim on terms that are not punitive to the 24% minority, and preserving the EUR 6.4 million of tax losses through the change of control. Each of these is uncertain, and the first has already failed once.
Downside is bounded in euro terms by the tiny market capitalisation, but it is real in percentage terms. Liquidation, or a highly dilutive recapitalisation at today's depressed price, would leave little for minorities. Trading is so thin that even entering or exiting a small position is impractical.
Verdict: Cumulex is uninvestable on fundamentals and is a speculative special-situation option only for investors comfortable with sponsor dependence and related-party risk. The key monitorable is the content and pricing of any Value8 debt-conversion or asset-injection proposal, together with the renewal of Value8's letter of support beyond June 2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Prior / other roles | Age | Compensation FY2025 | Source |
|---|---|---|---|---|---|---|
Drs. Peter Paul F. de Vries | Chairman | Reappointed 16 Feb 2021 for up to 6 years; reappointed again 8 Jun 2026. Mandate start in current form 2021; earlier start date not publicly disclosed | Board member / CEO of Value8 NV (controlling shareholder) | Born 1967 (≈59) | EUR 0 (unpaid mandate) | AR FY2025; Beursgenoten/ShareCompany; VEB 2021 |
Drs. Gerben P. Hettinga | Managing director (gedelegeerd bestuurder) | As above | Board member of Value8 NV. Value8 AR 2021 lists a non-executive role at IEX Group NV | Born 1977 (≈49) | EUR 0 | AR FY2025; Value8 AR 2021; Beursgenoten |
Agnieszka Boekhout-Topolski | Director (new) | Appointed 8 Jun 2026 | Banking experience incl. ING Group; currently a customer expert at listed IFF | — | Not publicly disclosed (mandates historically unpaid) | Press release 9 Jun 2026 |
Noëlle van der Krogt | Director (new) | Appointed 8 Jun 2026 | Business economist; Business Controller at Bitvavo; focus on finance and compliance | — | — | Press release 9 Jun 2026 |
Frank Lagerveld (†) | Director (new) | Appointed 8 Jun 2026; died 26 Jun 2026 | Founder and director of Doornbos Lagerveld & Partners (Luxembourg); board and supervisory experience at listed companies | — | — | Press releases 9 Jun 2026 and 31 Jul 2026 |
“—” = not publicly disclosed.
Governance Overview
| Metric | Pre-8 Jun 2026 | Post-26 Jun 2026 |
|---|---|---|
Board size | 2 | 4 |
Value8-affiliated directors | 2 | 2 |
Directors not affiliated with Value8 | 0 | 2 |
Women on board | 0 | 2 |
Chair / CEO separation | No CEO exists; the chair is a Value8 director | Unchanged |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
11 May 2026 | Board expansion announced ahead of AGM | Press release |
8 Jun 2026 | Three new directors appointed; de Vries and Hettinga reappointed | Response to governance gaps flagged by the auditor |
26 Jun 2026 | F. Lagerveld deceased | Board reverts to 4 members |
Major Shareholders
| Holder | Votes | % of votes | Type | Source |
|---|---|---|---|---|
Value8 NV (Bussum, NL) | 416,650 | 75.75 | Shares / profit certificates | AR FY2025; transparency register |
Jacobus Pieter Visser (Nieuwkoop, NL) | 40,000 | 7.27 | Shares / profit certificates | AR FY2025 |
Free float / undisclosed holders | 93,350 | 16.98 | — | Analyst calc. (550,000 − 456,650) |
Competitive Landscape
Competitor Detail
| Alternative route to a listing | Example (named only where verified) | Positioning vs Cumulex |
|---|---|---|
Sister shell controlled by the same sponsor | MKB Nedsense NV (Euronext Amsterdam), in which Value8 holds a majority stake | Same sponsor (Value8); competes for the same pipeline of injectable assets |
Traditional IPO on Euronext Brussels / Growth / Access | Not company-specific | More expensive and slower, but no legacy liabilities; Cumulex offers speed and an existing listing |
SPAC / blank-cheque vehicles | Not company-specific | Usually come with trust cash; Cumulex has none and carries EUR 2.5m of related-party debt |
Other dormant Euronext shells | — | Comparable revenue, margins and R&D data are not publicly disclosed for a benchmark set |
Competitor Detail — Revenue
| Metric (FY2025) | Cumulex NV |
|---|---|
Revenue (EUR) | 0 |
R&D intensity | 0 |
Recent Developments
Every identifiable dated event is listed, including relevant parent-company (Value8) events, which are flagged.
Categories with no events: contract wins, product launches, guidance revisions, litigation, regulatory sanctions, layoffs and hiring.



